Trials / Completed
CompletedNCT00083525
Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- Sponsor
- Heidelberg Pharma AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of the combination of WX-UK1 and capecitabine in patients with advanced malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | WX-UK1 in combination with Capecitabine |
Timeline
- Start date
- 2004-05-01
- First posted
- 2004-05-26
- Last updated
- 2008-01-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00083525. Inclusion in this directory is not an endorsement.